AbbVie Defends Humira With Aggressive Discount In First EU Tender
AbbVie has reportedly slashed the price of its TNF inhibitor Humira by 80% in the first European tender for biosimilar adalimumab, far beyond the 50% discount previously thought.
You may also be interested in...
Decreasing Humira’s ex-US sales guidance for the second time in three months caught significant attention, as AbbVie now expects 30% revenue erosion for its top-seller outside its home market.
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.
A look back at the Scrip stories that piqued the most interest for our readers in 2018.